Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial ClarityBenzinga • 07/19/24
AGEN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm!Accesswire • 07/19/24
$6.6 Bn Herpes Simplex Virus Infections Markets - Global Strategic Business Report to 2030 with Coverage of 10+ Major Players Including Admedus, Agenus, and Aicuris Anti-infective CuresGlobeNewsWire • 07/19/24
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm!Accesswire • 07/18/24
Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapyInvezz • 07/18/24
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal CancerBusiness Wire • 07/18/24
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI ConferenceBusiness Wire • 06/28/24
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical StudiesBusiness Wire • 06/27/24
Nature Medicine Reports Agenus' Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50Business Wire • 06/13/24
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual MeetingBusiness Wire • 05/23/24
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire • 05/23/24
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal CancerBusiness Wire • 05/16/24